Andrew Brackmann

Can you maybe just sort of talk about any specific investments that are going to those areas in 2026 or in 2027?

as you sort of think potentially about monetizing some of this longer term or maybe even partnering with some of these AI companies

how do you balance those types of distribution partnerships with potentially doing some of this testing yourselves in the future?

You maybe help us size that as a broader opportunity? And what further investments are you making there?

how it's set up today to withstand any demand pressures from unemployment rates going higher, how does that sort of -- how has it changed

can you maybe just sort of shed a little bit more light on any volume or reimbursement expectations for that asset in 2025

can you maybe talk about that target in the context of how international plays into the buildup there?

Can you maybe pick that apart a bit more for us? And I guess, how should we be thinking about the go forward there

I think you called out organic pricing up in the quarter. Can you maybe just peel that back a bit for us just in terms of the key drivers there?

can you maybe sort of talk about underlying inflation assumptions and how those might impact margins this year?

talk about the acquisition in that lens now that it's sort of been a part of the company for some time

how should we think about your appetite to continue to do acquisitions or partnerships

does this sort of change, how you're sort of viewing payers' willingness to potentially expand reimbursement